• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PKR 与 4.1R 结合促进肝癌的锚定非依赖性生长,导致预后不良。

PKR associates with 4.1R to promote anchorage-independent growth of hepatocellular carcinoma and lead to poor prognosis.

机构信息

Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime, 791-0295, Japan.

Division of Molecular Pathology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

出版信息

Sci Rep. 2024 Nov 13;14(1):27768. doi: 10.1038/s41598-024-75142-5.

DOI:10.1038/s41598-024-75142-5
PMID:39532917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11557841/
Abstract

RNA-dependent protein kinase (PKR) may have a positive regulatory role in controlling tumor growth and progression in hepatocellular carcinoma (HCC). However, the downstream substrates and the molecular mechanism of PKR in the growth and progression of HCC have not been clarified. In this study, mass spectrometry analysis was performed with immunoprecipitated samples, and 4.1R was identified as a protein that binds to PKR. In transfected COS7 cells, an immunoprecipitation experiment showed that 4.1R binds to wild-type PKR, but not to a kinase-deficient mutant PKR, suggesting that PKR binds to 4.1R in a kinase activity-dependent manner. In HCC cell lines, HuH7 and HepG2, the expression level of 4.1R protein was shown to be regulated by protein expression and activation of PKR. Interestingly, high expression of 4.1R, as well as PKR, is associated with a worse prognosis in HCC. PKR increased HCC cell growth in both anchorage-dependent and anchorage-independent manners, whereas 4.1R was involved in HCC cell growth only in an anchorage-independent manner, not in an anchorage-dependent manner. The rescue experiment indicated that increased anchorage-independent growth of HCC cells by PKR might be caused by 4.1R. In conclusion, PKR associates with 4.1R and promotes anchorage-independent growth of HCC. The PKR-4.1R axis might be a new therapeutic target in HCC.

摘要

RNA 依赖性蛋白激酶(PKR)可能在控制肝癌(HCC)的肿瘤生长和进展方面具有正向调节作用。然而,PKR 在 HCC 生长和进展中的下游底物和分子机制尚未阐明。在这项研究中,通过免疫沉淀样品进行了质谱分析,鉴定出 4.1R 是与 PKR 结合的蛋白。在转染的 COS7 细胞中,免疫沉淀实验表明 4.1R 与野生型 PKR 结合,但不与激酶缺陷型突变 PKR 结合,提示 PKR 以激酶活性依赖的方式与 4.1R 结合。在 HCC 细胞系 HuH7 和 HepG2 中,PKR 的蛋白表达和激活调节 4.1R 蛋白的表达水平。有趣的是,4.1R 和 PKR 的高表达与 HCC 的预后不良相关。PKR 以依赖锚定和不依赖锚定的方式增加 HCC 细胞的生长,而 4.1R 仅在不依赖锚定的方式,而不是依赖锚定的方式参与 HCC 细胞的生长。挽救实验表明,PKR 可能通过 4.1R 引起 HCC 细胞不依赖锚定的生长增加。总之,PKR 与 4.1R 相关,并促进 HCC 的不依赖锚定的生长。PKR-4.1R 轴可能是 HCC 的一个新的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/92e15fb1bfd0/41598_2024_75142_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/e75599e8fce5/41598_2024_75142_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/d1bcffdfc62b/41598_2024_75142_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/868252f58dfc/41598_2024_75142_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/783e6bb3d8b0/41598_2024_75142_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/d32733fb7c14/41598_2024_75142_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/92e15fb1bfd0/41598_2024_75142_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/e75599e8fce5/41598_2024_75142_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/d1bcffdfc62b/41598_2024_75142_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/868252f58dfc/41598_2024_75142_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/783e6bb3d8b0/41598_2024_75142_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/d32733fb7c14/41598_2024_75142_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf01/11557841/92e15fb1bfd0/41598_2024_75142_Fig6_HTML.jpg

相似文献

1
PKR associates with 4.1R to promote anchorage-independent growth of hepatocellular carcinoma and lead to poor prognosis.PKR 与 4.1R 结合促进肝癌的锚定非依赖性生长,导致预后不良。
Sci Rep. 2024 Nov 13;14(1):27768. doi: 10.1038/s41598-024-75142-5.
2
Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection.蛋白激酶 R 调节 c-Fos 和 c-Jun 信号通路促进丙型肝炎病毒感染相关性肝细胞癌的增殖。
PLoS One. 2013 Jul 2;8(7):e67750. doi: 10.1371/journal.pone.0067750. Print 2013.
3
Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation.受刺激的肝星状细胞通过蛋白激酶 R 的激活促进肝细胞癌的进展。
PLoS One. 2019 Feb 22;14(2):e0212589. doi: 10.1371/journal.pone.0212589. eCollection 2019.
4
Reduction of double-stranded RNA-activated protein kinase in hepatocellular carcinoma associated with hepatitis B virus.乙型肝炎病毒相关肝细胞癌中双链RNA激活蛋白激酶的降低
J Med Virol. 2004 Jun;73(2):187-94. doi: 10.1002/jmv.20074.
5
High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma.ADAM8 高表达与肝癌患者预后不良相关。
Pathol Oncol Res. 2013 Jan;19(1):79-88. doi: 10.1007/s12253-012-9560-6. Epub 2012 Sep 12.
6
WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.WTAP 通过 m6A-HuR 依赖的 ETS1 表观遗传沉默促进肝细胞癌进展。
Mol Cancer. 2019 Aug 22;18(1):127. doi: 10.1186/s12943-019-1053-8.
7
Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma.HOXA1的过表达与肝细胞癌患者的不良预后相关。
Tumour Biol. 2012 Dec;33(6):2125-34. doi: 10.1007/s13277-012-0472-6. Epub 2012 Aug 4.
8
Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells.丙型肝炎病毒核心蛋白对PKR的苏氨酸446磷酸化作用会破坏肝癌细胞中的G2/M期。
J Cell Physiol. 2005 Oct;205(1):25-31. doi: 10.1002/jcp.20363.
9
Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation.自分泌EDIL3水平升高通过RGD介导的整合素激活保护肝细胞癌免受失巢凋亡。
Mol Cancer. 2014 Oct 1;13:226. doi: 10.1186/1476-4598-13-226.
10
Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer.高表达的 HDGF 作为一个独立的预后因素与中国肝癌患者的不良预后相关。
Diagn Pathol. 2010 Sep 16;5:58. doi: 10.1186/1746-1596-5-58.

本文引用的文献

1
The protein 4.1R downregulates VEGFA in M2 macrophages to inhibit colon cancer metastasis.蛋白 4.1R 下调 M2 巨噬细胞中的 VEGFA 以抑制结肠癌转移。
Exp Cell Res. 2021 Dec 1;409(1):112896. doi: 10.1016/j.yexcr.2021.112896. Epub 2021 Oct 27.
2
Comprehensive understanding of anchorage-independent survival and its implication in cancer metastasis.全面理解锚定非依赖性生存及其在癌症转移中的意义。
Cell Death Dis. 2021 Jun 18;12(7):629. doi: 10.1038/s41419-021-03890-7.
3
CADM1 promotes malignant features of small-cell lung cancer by recruiting 4.1R to the plasma membrane.
CADM1 通过将 4.1R 募集到质膜上来促进小细胞肺癌的恶性特征。
Biochem Biophys Res Commun. 2021 Jan 1;534:172-178. doi: 10.1016/j.bbrc.2020.11.121. Epub 2020 Dec 6.
4
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.肝细胞癌的试验设计与终点:美国肝病研究学会共识会议
Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9.
5
Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo.PKR 抑制剂 C16 抑制肝癌细胞增殖和血管生成的体内外治疗作用。
Sci Rep. 2020 Mar 20;10(1):5133. doi: 10.1038/s41598-020-61579-x.
6
Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma.Nqo1 活性的调节阻断了肝癌的失巢凋亡抵抗并降低了其转移潜能。
Cancer Sci. 2020 Apr;111(4):1228-1240. doi: 10.1111/cas.14320. Epub 2020 Mar 3.
7
Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC.更正:蛋白质4.1N作为一种潜在的肿瘤抑制因子,将蛋白磷酸酶1与非小细胞肺癌中的JNK-c-Jun信号通路调节联系起来。
Oncotarget. 2019 Oct 22;10(58):6285. doi: 10.18632/oncotarget.27282.
8
Hepatocellular Carcinoma.肝细胞癌
N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.使用独立数据集的表达数据验证 miRNA 在肝细胞癌中的预后能力。
Sci Rep. 2018 Jun 15;8(1):9227. doi: 10.1038/s41598-018-27521-y.